Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

New once-a-month drug could treat diabetes and obesity, scientists say - Researchers say experimental drug’s less frequent ...

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...

MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...